News

25 November, 2025

Genekor Participation at the 11th Hellenic Breast Surgery Society Congress (EXEM)

Genekor attended the 11th Hellenic Congress of the Breast Surgery (EXEM), held in Athens from 14 to 16 November 2025 at the Royal Olympic Hotel, contributing to the scientific dialogue on current developments in breast cancer diagnostics and clinical management.

Scientific Presentation – Oncotype DX and 12-Year Clinical Evidence

During the congress, Genekor delivered the presentation:

“Predicting Chemotherapy Benefit in Early Breast Cancer with 12-Year Level 1A Evidence: Clinical Utility in Daily Practice.”

• Speaker: Dr. Phoebus Heracleides

• The session was chaired by Dr. N. Pazaïti and Dr. F. Poulakaki.

The presentation highlighted updated 12-year clinical data on Oncotype DX, with emphasis on N0 patients, and demonstrated how the assay supports evidence-based and individualized treatment decision-making in routine clinical practice.

Contributions to the Scientific Program

Genekor also participated in the main scientific program with two additional presentations:

• Clinical utility of Oncotype DX in patients considered for CDK4/6 inhibitor therapy.

• Accuracy and clinical application of liquid biopsy in breast cancer.

The presentations focused on current advances in molecular diagnostics and their role in optimizing clinical decision pathways.

Research Work Presented via e-Posters

Genekor contributed two e-posters to the congress:

• Comparative evaluation of FISH and IHC for HER2 assessment in breast cancer: Clinical value of FISH.
  

• Reclassification of VUS findings in BRCA1, BRCA2 and PALB2 according to ClinGen VCEPs, aiming to refine previous classifications based on ACMG/AMP guidelines.
  

The e-posters addressed key aspects of molecular interpretation, variant classification, and the continuous enhancement of diagnostic accuracy in breast cancer testing.

It was a pleasure meeting everyone there.